Smith & Nephew (LON:SN) Insider David King Acquires 2,800 Shares

Key Points

• Insider David King purchased 2,800 shares of Smith & Nephew at an average cost of GBX 3,631 per share, amounting to £101,668.
• Analyst ratings indicate an average of "Hold" for the stock, with target price revisions ranging from GBX 1,100 to GBX 1,438 by various financial institutions.
• Smith & Nephew has a market capitalization of £14.78 billion, with a price-to-earnings ratio of 48.53 and a debt-to-equity ratio of 70.22.

Smith & Nephew plc (LON:SN - Get Free Report) insider David King bought 2,800 shares of the business's stock in a transaction on Monday, August 18th. The stock was purchased at an average price of GBX 3,631 per share, for a total transaction of £101,668.

Smith & Nephew Price Performance

SN traded down GBX 6 during mid-day trading on Friday, hitting GBX 1,385. The stock had a trading volume of 1,372,119 shares, compared to its average volume of 343,671. The business's fifty day simple moving average is GBX 1,180.15 and its two-hundred day simple moving average is GBX 1,102.83. The company has a debt-to-equity ratio of 70.22, a current ratio of 2.51 and a quick ratio of 0.84. The firm has a market cap of £15.18 billion, a price-to-earnings ratio of 49.87, a price-to-earnings-growth ratio of 0.46 and a beta of 0.62.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the stock. JPMorgan Chase & Co. increased their price objective on shares of Smith & Nephew from GBX 1,357 to GBX 1,438 and gave the stock an "overweight" rating in a research report on Wednesday, August 6th. Deutsche Bank Aktiengesellschaft increased their price objective on shares of Smith & Nephew from GBX 1,300 to GBX 1,400 and gave the stock a "hold" rating in a research report on Wednesday, August 6th. Finally, Berenberg Bank increased their price objective on shares of Smith & Nephew from GBX 1,100 to GBX 1,300 and gave the stock a "hold" rating in a research report on Thursday, August 7th. One equities research analyst has rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of GBX 1,379.33.

About Smith & Nephew

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.